Wexford Capital LP Aerie Pharmaceuticals Inc Transaction History

Wexford Capital LP

  • $382 Million
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 13, 2021
SELL
$13.12 - $20.9 $40,685 - $64,810
-3,101 Closed
0 $0
Q4 2020

Feb 16, 2021
BUY
$9.12 - $14.49 $28,281 - $44,933
3,101 New
3,101 $42,000
Q3 2019

Nov 14, 2019
SELL
$18.41 - $28.0 $832,132 - $1.27 Million
-45,200 Closed
0 $0
Q2 2019

Aug 14, 2019
BUY
$28.97 - $48.21 $1.31 Million - $2.18 Million
45,200 New
45,200 $1.34 Million

Others Institutions Holding AERI

# of Institutions
3
Shares Held
2.4M
Call Options Held
0
Put Options Held
0
View Full List

About AERIE PHARMACEUTICALS INC

AERI Quotes by TradingView
  • Ticker AERI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 49,390,500
  • Description
  • Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...
More about AERI
Track This Portfolio

Track Wexford Capital LP Portfolio

Follow Wexford Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wexford Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Wexford Capital LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email